FDA's cancer drugs committee is anxious to approve
Post# of 72440
Quote:
[FDA's committee] has typically used some liberal assessments in reviewing new drugs, anxious to provide approvals in cases where docs want more options, or no drugs are currently approved .
But, Daiichi Sankyo "lost" the data for the 25th week of their clinical trial. FDA is not amused.
https://endpts.com/daiichi-sankyo-faces-fda-c...-drug-oks/